InvestorsHub Logo
Followers 117
Posts 18727
Boards Moderated 0
Alias Born 08/27/2005

Re: NASDAQ2020 post# 325428

Thursday, 12/19/2019 2:17:32 AM

Thursday, December 19, 2019 2:17:32 AM

Post# of 400844
Kayak wench is correct. Nasrat made it pretty clear that Elite is not pursuing any type of ADF for opioids. In fact there are companies that are trying to unload their ADF formulations because there is no money to be made on them. Many formulations are way too expensive. Elite was offered ADF formulations and did not want them.

Even CNS drugs like Adderall and recent articles about abuse deterent versions were brought up. NH is not going to spend money and time on ADF versions of CNS drugs when the FDA is doing much the same thing with them as they are doing with opioids. If people want to abuse CNS drugs, until the FDA says otherwise, let them abuse.

The FDA is not seeking ADFs to replace or counter opioid formulations. That is the picture I got out of the SHM. And I do not think Elite is pursuing the much cheaper ADF without naltrexone. Right now opioids are on the shelf due to lawsuits, and an inconsistent FDA that really doesn't know what the hell it wants. Sound like someone familiar?


So unless you heard something from Dianne who has contacted NH about the
new ADF formulation, I would say Elite is going in another direction.


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News